GSK: gets positive opinion for long-acting HIV treatment

(CercleFinance.com) - GSK's ViiV Healthcare said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending its long-acting treatment of HIV, that can be dosed once-monthly or once every two-months.


The recommendation is for a combination of Vocabria injection and tablets with Rekambys injection and Edurant tablets in adults who are still virologically suppressed on a stable antiretroviral regimen.

If approved, the treatment would become the first complete long-acting regimen, dosed once-monthly or once every 2-months, for virologically suppressed people living with HIV-1 across Europe.

Copyright (c) 2020 CercleFinance.com. All rights reserved.